EMMA (Emmaus Life Sciences) Total Liabilities: $86.56 Mil (As of Mar. 2026)


What is Emmaus Life Sciences Total Liabilities?

Emmaus Life Sciences EMMA Total Liabilities is $86.56 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Emmaus Life Sciences's Total Liabilities for the quarter that ended in Mar. 2026 was $86.56 Mil.

Emmaus Life Sciences's quarterly Total Liabilities increased from Sep. 2025 ($80.24 Mil) to Dec. 2025 ($85.04 Mil) and increased from Dec. 2025 ($85.04 Mil) to Mar. 2026 ($86.56 Mil).

Emmaus Life Sciences's annual Total Liabilities declined from Dec. 2023 ($82.94 Mil) to Dec. 2024 ($80.08 Mil) but then increased from Dec. 2024 ($80.08 Mil) to Dec. 2025 ($85.04 Mil).

Emmaus Life Sciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Total Liabilities Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.18 82.32 82.94 80.08 85.04

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.08 79.05 80.24 85.04 86.56

Emmaus Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Emmaus Life Sciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=69.072+(3.68+12.292
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=85.04

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=21.436--63.608
=85.04

Emmaus Life Sciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=70.537+(3.601+12.418
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=86.56

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=18.696--67.86
=86.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $86.56 Mil mean?
Emmaus Life Sciences (EMMA) has a Total Liabilities of $86.56 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Total Liabilities too high?
Emmaus Life Sciences' current Total Liabilities is $86.56 Mil.
How does Emmaus Life Sciences' Total Liabilities compare to CERO and AGTX?
Emmaus Life Sciences' Total Liabilities of $86.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Total Liabilities is $86.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Total Liabilities is $86.56 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Total Liabilities is $86.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.